Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
1,140 results
  • In vitro antineoplastic effects of auranofin in canine lymphoma cells. [Journal Article]
  • BCBMC Cancer 2018 May 03; 18(1):522
  • Zhang H, Rose BJ, … Thamm DH
  • CONCLUSIONS: Auranofin appears to inhibit the growth and initiate apoptosis in canine lymphoma cells in vitro at clinically achievable concentrations. Therefore, this agent has the potential to have near-term benefit for the treatment of canine lymphoma, as well as a translational model for human lymphoma. Decreased TrxR activity and increasing ROS production may be useful biomarkers of drug exposure.
  • Comparative oncology approach to drug repurposing in osteosarcoma. [Journal Article]
  • PlosPLoS One 2018; 13(3):e0194224
  • Parrales A, McDonald P, … Fulbright JM
  • CONCLUSIONS: Auranofin, alone or in combination with rapamycin or vorinostat, may be useful new treatment strategies for OS. Future studies may evaluate the efficacy of auranofin in dogs with OS as a prelude to human clinical evaluation.
  • Deubiquitinase Inhibitor Auranofin Attenuated Cardiac Hypertrophy by Blocking NF-κB Activation. [Journal Article]
  • CPCell Physiol Biochem 2018; 45(6):2421-2430
  • Hu M, Zhang Z, … Liu N
  • CONCLUSIONS: The present study indicated that Aur blocks the development of left ventricular hypertrophy induced by abdominal aortic constriction. This phenomenon might be attributed to inhibition of the 19S proteasome-associated deubiquitinase that can lead to aggregation of IκBα and inactivation of the NF-κB pathway. Thus, Aur could be a potential anti-cardiac hypertrophy agent.
New Search Next